It's Showtime for Thermo Fisher Scientific
Thermo Fisher Scientific (NYS: TMO) is expected to report Q3 earnings on Oct. 24. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Thermo Fisher Scientific's revenues will grow 0.8% and EPS will grow 8.4%.
The average estimate for revenue is $3.00 billion. On the bottom line, the average EPS estimate is $1.16.
Revenue details
Last quarter, Thermo Fisher Scientific reported revenue of $3.11 billion. GAAP reported sales were 8.9% higher than the prior-year quarter's $2.85 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
Last quarter, non-GAAP EPS came in at $1.22. GAAP EPS of $0.63 for Q2 were 53% lower than the prior-year quarter's $1.35 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Recent performance
For the preceding quarter, gross margin was 42.9%, 170 basis points better than the prior-year quarter. Operating margin was 13.1%, 70 basis points better than the prior-year quarter. Net margin was 7.5%, 1,080 basis points worse than the prior-year quarter.
Looking ahead
The full year's average estimate for revenue is $12.28 billion. The average EPS estimate is $4.82.
Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 552 members out of 573 rating the stock outperform, and 21 members rating it underperform. Among 155 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 152 give Thermo Fisher Scientific a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Thermo Fisher Scientific is outperform, with an average price target of $63.00.
Add Thermo Fisher Scientific to My Watchlist.
The article It's Showtime for Thermo Fisher Scientific originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Thermo Fisher Scientific. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
